Company / Accounts Receivable
Emergent BioSolutions Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$84.2M
FY2025
5-year range
$84.2M / $274.7M
FY2021-FY2025
Trend
-45.5%
vs FY2024
Sector context
#61 of 113
Health Care
What the data says
At $84M, Emergent BioSolutions Inc.'s accounts receivable ranks #61 of 113 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $84M in FY2025 to $275M in FY2021.
Based on SEC 10-K filings.
$84M in FY2025 with a 5-year CAGR of -18.3%.
Declined from $191M to $84M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -19.1%
- 5-Year CAGR
- -18.3%
- 10-Year CAGR
- -
Sector benchmark
#61 of 113 in Health CareTop 54% of 113This company $84.2M Sector average $1.1B
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -18.3%, indicating a declining trend.
- In FY2025, accounts receivable decreased 45.5% year-over-year.
- Ranks #61 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.2M | -45.5% |
| FY2024 | $154.5M | -19.1% |
| FY2023 | $191.0M | +20.0% |
| FY2022 | $159.2M | -42.0% |
| FY2021 | $274.7M | +19.0% |
| FY2020 | $230.9M | -14.7% |
| FY2019 | $270.7M | +3.1% |
| FY2018 | $262.5M | +82.7% |
| FY2017 | $143.7M | +3.8% |
| FY2016 | $138.5M | +21.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026